Article

Screening DNA-targeted anticancer drug in vitro based on the drug-conjugated DNA by resonance light scattering technique

Department of Chemistry, Shantou University, Daxue Road 243#, Shantou 515063, China.
Biosensors & Bioelectronics (Impact Factor: 6.45). 04/2010; 25(8):1947-52. DOI: 10.1016/j.bios.2010.01.011
Source: PubMed

ABSTRACT A sensitive and reliable assay has been developed to directly screen DNA-targeted anticancer drugs in vitro via using resonance light scattering (RLS) technique. The results of experiments displayed that the increment of RLS intensity was directly proportional to the antitumor effect of anticancer drugs. Through the RLS spectra, the activities of four drugs have been demonstrated as mitoxantrone (MIT)>epirarubicin (EPI)>daunorubicin (DAU)>adriamycin (ADM). However, to further verify the activities of the above four drugs, binding constant (k) for each of them has been calculated by RLS technique as follows: k(RLS) (MIT, 8.75 x 10(5) L mol(-1))>k(RLS) (EPI, 6.58 x 10(5) L mol(-1))>k(RLS) (DAU, 4.79 x 10(5) L mol(-1))>k(RLS) (ADM, 3.82 x 10(5) L mol(-1)). Also, this RLS assay result was validated by seasoned vitro screening methods for anticancer drugs. In all, the proposed RLS is not only a simple, sensitive, objective and straightforward method, but also it is an unprecedented assay for primarily screening DNA-targeted anticancer drugs.

0 Followers
 · 
89 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the study, a new assay of vascular endothelial growth factor (VEGF) has been developed by the use of gold nanoparticles (GNPs)–anti-VEGF conjugates. The immunoreaction between GNPs–anti-VEGF conjugates and VEGF took place in pH 7.5 PBS buffer solution after the addition of VEGF. The formation of GNPs modified VEGF immunocomplex resulted in the enhanced resonance light scattering (RLS) intensity at 388.0 nm. Under the optimal conditions, the magnitude of enhanced RLS intensity (ΔI RLS) was proportional to the VEGF concentration in the range from 100 to 1,500 pg mL−1, with a detection limit of 60 pg mL−1. The surface plasma resonance absorption spectrum, the characteristics of RLS, the VEGF immunocomplex, and the optimum conditions of the immunoreaction have all been investigated. The VEGF concentrations of 20 serum specimens detected by the developed assay showed consistent results in comparison with those obtained by commercially available enzyme-linked immunosorbent assay kit.
    Plasmonics 06/2013; 8(2). DOI:10.1007/s11468-012-9442-5 · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oridonin is an effective anticancer drug which has high potency and low systemic toxicity. In this study, the interaction between oridonin and bovine serum albumin (BSA) was investigated by several spectroscopic approaches for the first time. The binding characteristics of oridonin and BSA were determined by fluorescence emission spectra and resonance light scattering spectra. It is showed that the oridonin quenches the fluorescence of BSA and the static quenching constant K-SV is 1.30 x 10(4) L mol(-1) at 298 K. Moreover, oridonin and BSA form a 1:1 complex with a binding constant of 0.62 x 104 L mol(-1). On the other hand, the thermodynamic parameters indicate that the binding process was a spontaneous molecular interaction procedure, in which hydrophobic forces played a major role. The structure analysis indicates that oridonin binding results in an increased hydrophobicity around the tryptophan residues of BSA. Additionally, as shown by the UV-vis absorption, synchronous fluorescence and three-dimensional fluorescence results, oridonin could lead to conformational and some microenvironmental changes of BSA. The work provides accurate and full basic data for clarifying the binding mechanism of oridonin with BSA in vitro and is helpful for understanding its effect on protein function during its transportation and distribution in blood. (c) 2012 Elsevier B.V. All rights reserved.
    Journal of Luminescence 02/2013; 134:863-869. DOI:10.1016/j.jlumin.2012.06.035 · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We have developed a method to investigate the interaction between DNA-targeted anthracyclines and DNA in the presence of the drug paclitaxel. It is based on resonance light scattering (RLS) and on the finding that anthracyclines when bound to DNA undergo a dramatic enhancement in their RLS intensities, while paclitaxel does not display such an effect. However, the RLS intensities of the anthracyclines-DNA associates are remarkably enhanced again on addition of paclitaxel. UV-visible spectra reveal interactions between paclitaxel and anthracyclines, but no reaction between paclitaxel and DNA. Consequently, paclitaxel, though not DNA-targeted, can improve the DNA-binding capabilities of anthracyclines. Binding constants between anthracyclines and DNA, and improved efficiency of paclitaxel on the DNA-binding capabilities of anthracyclines were calculated. The DNA binding constants of doxorubicin, epirubicin, and mitoxantrone, respectively, are 4.53 × 105 L mol−1, 6.05 × 105 L mol−1, and 9.47 × 105 L mol−1. The improved values in presence of paclitaxel are 78%, 47% and 19%. We also have investigated the effects of drug concentrations and the order of adding the drugs. Displacement studies (using methylene blue as a competitive agent) provided additional information on the mechanisms of the interaction between paclitaxel and anthracyclines. Figure A novel resonance light scattering (RLS) method for the investigation on the interaction between anthracyclines and DNA in the presence of paclitaxel has been developed based on the enhanced RLS intensities.
    Microchimica Acta 04/2011; 177(1-2). DOI:10.1007/s00604-011-0747-4 · 3.72 Impact Factor